BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28454473)

  • 1. Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.
    Qin YZ; Zhang YH; Qin XY; Zhu HH
    Oncol Lett; 2017 Apr; 13(4):2823-2830. PubMed ID: 28454473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma.
    Yang L; Dao FT; Chang Y; Wang YZ; Li LD; Chen WM; Long LY; Liu YR; Lu J; Liu KY; Qin YZ
    Onco Targets Ther; 2020; 13():7545-7553. PubMed ID: 32801773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies.
    Schenk T; Stengel S; Goellner S; Steinbach D; Saluz HP
    Genes Chromosomes Cancer; 2007 Sep; 46(9):796-804. PubMed ID: 17534929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
    Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
    Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quantification of the PRAME transcripts in patients with acute myeloid leukemia].
    Zhu ZH; Qian J; Lin J; Yao DM; Qian Z; Wang YL; Chen Q; Han LX; Xiao G
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):149-52. PubMed ID: 20376794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
    Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
    Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
    Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia.
    Tajeddine N; Millard I; Gailly P; Gala JL
    Clin Chem Lab Med; 2006; 44(5):548-55. PubMed ID: 16681423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
    Schmelz K; Sattler N; Wagner M; Lübbert M; Dörken B; Tamm I
    Leukemia; 2005 Jan; 19(1):103-11. PubMed ID: 15510208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.
    Benetatos L; Hatzimichael E; Dasoula A; Dranitsaris G; Tsiara S; Syrrou M; Georgiou I; Bourantas KL
    Leuk Res; 2010 Feb; 34(2):148-53. PubMed ID: 19595458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
    Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
    Shiseki M; Ishii M; Ohwashi M; Wang YH; Tanaka N; Osanai S; Yoshinaga K; Mori N; Tanaka J
    Leuk Lymphoma; 2021 Oct; 62(10):2448-2456. PubMed ID: 34013846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation of the candidate tumor suppressor gene TCF21 in myelodysplastic syndrome and acute myeloid leukemia.
    Gu Y; Zhou JD; Xu ZJ; Zhang TJ; Wen XM; Ma JC; Ji RB; Yuan Q; Zhang W; Chen Q; Lin J; Qian J
    Am J Transl Res; 2019; 11(6):3450-3460. PubMed ID: 31312357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Implications on ZO-1 Gene Methylation in Myelodysplastic Syndrome Progression].
    Kang HY; Wang XR; Gao L; Wang W; Li MY; Wang LL; Wang CB; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):746-9. PubMed ID: 26117030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.